[go: up one dir, main page]

WO2011093559A1 - Composition pour la prévention ou le traitement du cancer de l'estomac, contenant de l'acide ursodésoxycholique en tant que principe actif - Google Patents

Composition pour la prévention ou le traitement du cancer de l'estomac, contenant de l'acide ursodésoxycholique en tant que principe actif Download PDF

Info

Publication number
WO2011093559A1
WO2011093559A1 PCT/KR2010/005080 KR2010005080W WO2011093559A1 WO 2011093559 A1 WO2011093559 A1 WO 2011093559A1 KR 2010005080 W KR2010005080 W KR 2010005080W WO 2011093559 A1 WO2011093559 A1 WO 2011093559A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
udca
apoptosis
cells
caspase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/005080
Other languages
English (en)
Korean (ko)
Inventor
한송이
임성철
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chosun University Industry Academic Cooperation Foundation
Original Assignee
Chosun University Industry Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chosun University Industry Academic Cooperation Foundation filed Critical Chosun University Industry Academic Cooperation Foundation
Publication of WO2011093559A1 publication Critical patent/WO2011093559A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a composition for preventing or treating gastric cancer, which contains ursodeoxycholic acid (UDCA) as an active ingredient.
  • UDCA ursodeoxycholic acid
  • Stomach cancer is the highest cancer morbidity and cancer mortality in the world and is the most common cause of death from cancer in Korea, Japan, China, Russia, Central Europe, South and Central America, Hong Kong and Scandinavia. More than 16% of Korean and Japanese men are dying from stomach cancer.
  • the incidence rate of gastric cancer is higher than that of other continental races. It is reported to come from a difference.
  • the daily salt intake is about 20g, which is twice as much as that of Westerners.
  • the incidence of gastric cancer is reported in Korea, Japan, Finland, and Iceland, which have a habit of eating salted fish.
  • genetic causes other than eating habits are involved, and it is known that the incidence of gastric cancer is high in the first generation offspring of gastric cancer patients.
  • the symptoms of gastric cancer show a variety of symptoms ranging from no symptoms to severe pain, the symptoms of gastric cancer does not have any characteristics but general digestive symptoms, most of the early symptoms of stomach cancer And, even if the symptoms are relatively mild to feel a slight indigestion or upper abdominal discomfort, most people are easy to overlook this, causing the death rate of stomach cancer.
  • Surgical surgery is effective for removing tumor tissue or surrounding tissue but cannot be used to treat tumors in difficult-to-operate areas such as the spine or to disperse diffuse tumors scattered throughout the body, such as leukemia.
  • Chemotherapy can treat cancer by disrupting cell replication or cell metabolism, but can be used for the treatment of various tumors, but it also acts on normal cells, causing serious side effects. In particular, it acts on hematopoietic organs in which cell division and cell metabolism are active, causing serious side effects that weaken the patient's immune system.
  • ursodeoxycholic acid (3 ⁇ , 7 ⁇ -dihydroxy-5 ⁇ -cholanoic acid, hereinafter referred to as 'UDCA') has been used for liver, biliary system diseases in Korea, China, and Japan for a long time.
  • 'UDCA' ursodeoxycholic acid
  • the UDCA has a function of cleaning the microbilitery in vivo, thus releasing wastes and toxic bile acids in the microbilitery, stabilizing and protecting hepatocytes, increasing hepatic blood flow, inhibiting cholesterol absorption and biosynthesis, It has the effect of dissolving gallstones, inhibiting production, and pharmacological activity to normalize immune activity. It is a drug used with major clinical indications for gallstones and biliary tract diseases, chronic liver disease and liver function improvement, indigestion after small intestine resection and fatty liver. .
  • the mechanism of cholesterol gallstone dissolving effect of UDCA decreases the activity of HMG CoA reductase, an enzyme required for cholesterol synthesis in the liver, reduces cholesterol secretion into bile, increases 7 ⁇ -hydroxylase activity, and absorbs cholesterol in the intestine. It is known to act to lower.
  • administration of UDCA transforms cholesterol-saturated bile into unsaturated bile. Desaturation of bile resulting from the administration of UDCA increases the ability to transport cholesterol and is a highly soluble multilamellar liposome in bile. (multilamellar liposome (mesophase)) forms liquid crystals in bile saturated with cholesterol. Therefore, gallstones are dissolved in bile supersaturated with cholesterol after UDCA due to the formation of liquid crystals.
  • UDCA is widely used as a therapeutic agent for liver-related diseases, and recently, it has been found that UDCA can effectively treat rectal cancer (Korean Patent Publication No. 2008-0061327), and is induced by environmental hormones including dioxin. It has also been reported that there is an effect that can suppress the toxicity (Republic of Korea Patent No. 0368936).
  • an object of the present invention is to provide a composition for preventing or treating gastric cancer, which comprises ursodeoxycholic acid (UDCA) or a salt thereof as an active ingredient.
  • UDCA ursodeoxycholic acid
  • It is another object of the present invention to provide an apoptosis inducer composition comprising urousodeoxycholic acid (UDCA) or a salt thereof as an active ingredient.
  • UDCA urousodeoxycholic acid
  • UDCA urousodeoxycholic acid
  • the present invention provides a composition for the prevention or treatment of gastric cancer comprising ursodeoxycholic acid (UDCA) or a salt thereof as an active ingredient.
  • UDCA ursodeoxycholic acid
  • the urousodeoxycholic acid (UDCA) or salts thereof may have anticancer activity by inducing apoptosis of gastric cancer cells to induce cell death.
  • the apoptosis is by the treatment of urosodeoxycholine acid (UDCA) or salts thereof, promoting the activity of caspase (gaspase) in gastric cancer cells; Promoting activity or expression of cell death receptors; Translocation of the protein kinase C (PKC) ⁇ protein from the cytosol to the membrane; Or by the generation of reactive oxygen species (ROS).
  • UDCA urosodeoxycholine acid
  • PDC protein kinase C
  • ROS reactive oxygen species
  • the caspase may be selected from the group consisting of caspase-3, caspase-6, caspase-8, caspase-9, and combinations thereof.
  • the cell death receptor may be selected from the group consisting of DR3, DR4, DR5, DR6, FAS, TNFR and combinations thereof.
  • promoting the activity or expression of the cell death receptor may be to induce apoptosis in gastric cancer cells by promoting the activity of FADD or RIP1 protein.
  • the generation of reactive oxygen species (ROS) or the activity of PKC (protein kinase C) ⁇ protein may be controlled by a lipid raft located in the cell membrane.
  • ROS reactive oxygen species
  • PKC protein kinase C
  • the urousodeoxycholic acid may be included in 50 ⁇ M ⁇ 5,000 ⁇ M relative to the total weight of the composition.
  • the present invention also provides an apoptosis inducer composition comprising urousodeoxycholic acid (UDCA) or a salt thereof as an active ingredient.
  • UDCA urousodeoxycholic acid
  • the composition may induce apoptosis in gastric cancer cells.
  • the present invention also provides a method for the prevention or treatment of gastric cancer, comprising administering urousodeoxycholic acid (UDCA) or a salt thereof to a subject in need thereof, including a human, with a pharmaceutically acceptable carrier. to provide.
  • UDCA urousodeoxycholic acid
  • the carrier may be one or more selected from the group consisting of diluents, lubricants, binders, disintegrants, sweeteners, stabilizers and preservatives.
  • Urosodeoxycholine acid or a salt thereof according to the present invention promotes the activity of caspase in gastric cancer cells, promotes the activity or expression of apoptosis receptors, promotes the activity of PKC and the activity of reactive oxygen species (ROS). Since it promotes production and ultimately induces apoptosis of gastric cancer cells, it can be usefully used for preventing or treating gastric cancer.
  • ROS reactive oxygen species
  • Figure 1A shows the concentration of UDCA and DCA (0, 250, 500, 1000 ⁇ M) for each cell line of gastric cancer cell lines snu-601, snu-638, snu-1 and snu-216, respectively, MTT assay It is a graph showing the comparison of the cell survival rate, apoptotic body percent and LDH activity percent through each,
  • Figure 1B shows the photo of the colony formed on the plate after the treatment of UDCA at each concentration for the gastric cancer cell lines
  • 1C is a graph showing counting the number of colonies formed.
  • FIG. 2A shows Z-DEVD-FMK, Z-VEID-FMK, Z-IETD-FMK, Z-LEHD-FMK, or Z-VAD-FMK, inhibitors of caspase 3, 6, 7, and 8 for gastric cancer cell lines
  • Figure 2B after treating 1000 ⁇ M UDCA to gastric cancer cell line, The results of measuring the activation of caspase-8 using a FLICE / Caspase 8-colorimetric assay kit are shown
  • FIG. 2C is first treated with Z-IETD-FMK in gastric cancer cell lines, followed by 1000 ⁇ M UDCA treatment.
  • Western blot shows the results of confirming the amount of protein cut caspase 3, 6 and PARP.
  • FIG. 3A shows siRNA FAS, siRNA DR4, siRNA DR5, or siRNA Control for gastric cancer cell lines snu-601 and snu-638 after transduction through AMAXA method, followed by 1000 ⁇ M UDCA, followed by HO / PI double
  • Figure 3B shows the result of confirming the protein amount of caspase 3, 6 and PARP cut through Western blot
  • Figure 3C is FLICE / The results of measuring the caspase-8 activation using the caspase 8-colorimetric assay kit are shown.
  • Figure 4A is transduced siRNA FADD, siRNA RIP1 or siRNA Control for the gastric cancer cell lines snu-601 and snu-638 through the AMAXA method, and then treated with 1000 ⁇ M UDCA, and then killed cells by HO / PI double staining
  • Figure 4B shows the result of measuring the degree (nucleus fragmentation or condensation of the nucleus)
  • Figure 4B shows the result of confirming the amount of protein of caspase 3, 6 and PARP, FADD and RIP1 cut through Western blot
  • Figure 4C The results of measuring caspase-8 activation using the FLICE / Caspase 8-color assay kit are shown.
  • Figure 5A is treated with 1000 ⁇ M UDCA for gastric cancer cell lines snu-601 and snu-638, followed by incubation with time, and then fractionated the cytosolic protein and organ / membrane protein fractions from the cells, respectively.
  • Western blot shows the results of confirming the amount of PKC ⁇ , PKC ⁇ , PKC ⁇ , and PKC ⁇ protein
  • Figure 5B is treated with a PKC inhibitor such as rottlerin (Rottlerin), and then HO / PI double staining method
  • the degree of cell death (nucleus fragmentation or nuclear condensation) and Western blot showed the expression level of DR5 protein and the amount of cut caspase 3 and 6 protein, and FIG.
  • 5C shows siRNA for each gastric cancer cell line.
  • PKC ⁇ or siRNA Control was transduced via AMAXA method, treated with 1000 ⁇ M UDCA, followed by HO / PI double staining to confirm the degree of cell death (nucleus fragmentation or nuclear condensation) and Western blot Via PKC The expression levels of the ⁇ and DR5 proteins and the amounts of the caspase 3, 6 and PKC ⁇ proteins that were truncated are shown.
  • FIG. 6A shows the results of measuring the production of ROS by treating 1000 ⁇ M UDCA against gastric cancer cell lines snu-601 and snu-638 and calculating the ratio of DCFH-DA / HO per cell after 3 hours or 5 hours.
  • 6B shows treatment of ROS inhibitors, 10 mM NAC, 100 ⁇ M BHA, 10 mM Tiron, 2 ⁇ M DPI, or 1000 U catalase, respectively, followed by 1000 ⁇ M UDCA treatment and HO / PI double staining for gastric cancer cell lines.
  • Degree nucleus fragmentation or nuclear condensation
  • FIG. 6C measures the amount of caspase-3, 6, and PARP protein truncated via Western blot for gastric cancer cell lines treated as in FIG. 6B above. The results are shown.
  • FIG. 7A shows that the snu-601 gastric cancer cell line was treated with 1000 ⁇ M UDCA in the presence or absence of 10 mM NAC or 100 ⁇ M BHA, respectively, and then the expression level of DR5 was confirmed by Western blotting
  • FIG. 7B is the snu-638 gastric cancer cell line. After treatment with 1000 ⁇ M UDCA in the presence or absence of 10 mM NAC or 100 ⁇ M BHA, respectively, the expression level of DR5 was confirmed by Western blot.
  • FIG. 8A shows pretreatment of 10 mM NAC to snu-601 gastric cancer cell line followed by 1000 ⁇ M UDCA and fractionation of cytosolic and organ / membrane protein fractions from cells, followed by Western blot for PKC ⁇ .
  • Figure 8B shows the measurement of the expression level
  • Figure 8B shows the measurement of the expression level of PKC ⁇ by performing the same experiment as in Figure 8A for the snu-638 gastric cancer cell line.
  • FIG. 10A shows that MBCD was previously treated in gastric cancer cell lines snu-601 and snu-638, and treated with 1000 ⁇ M UDCA, respectively, and cell viability was obtained through MTT assay, and the degree of cell death through HO / PI double staining (nucleus) Fragmentation or condensation of the nucleus),
  • FIG. 10B shows FLICE / Caspase 8-coloration, including the results of measuring the expression level of DR5 and the amount of caspase-3, 6, and PARP protein truncated by Western blot. The results of measuring the caspase-8 activation using the assay kit are shown.
  • FIG. 11A shows that 1 mM MBCD was pretreated with gastric cancer cell lines snu-601 and snu-638, and treated with 1000 ⁇ M UDCA, respectively, followed by fractionation of cytosolic protein and organ / membrane protein fractions from cells. , Western blot confirmed the amount of PKC ⁇ protein
  • Figure 11B is pre-treated with gastric cancer cell lines snu-601 and snu-638 MBM of 1mM or 2mM, and treated with 1000 ⁇ M UDCA, respectively, DCFH per cell
  • the result of ROS generation was measured by calculating the ratio of -DA / HO.
  • FIG. 12A and 12B show subcutaneous injection of 5 ⁇ 10 6 cells / 200 ul of snu-601 cells into the side of 6 week old Athymic balb / c nude mice, and the experimental group was treated with UDCA solution (150 mg / kg / day). , 6days / week), the control group to the control group (vehicle) by intraperitoneal injection as a result of analyzing the growth of xenograft tumor in vivo,
  • Figure 12A shows the size of the tumor (volume) formed on the side of the nude mouse It is a photograph
  • FIG. 12B is a result graph which shows the size of the tumor of the experimental group and a control group from the 14th to 33rd day. Statistical significance was confirmed by paired T-test.
  • the present invention is characterized by providing a composition for preventing or treating gastric cancer comprising ursodeoxycholic acid (UDCA) or a salt thereof as an active ingredient.
  • UDCA ursodeoxycholic acid
  • the pharmacologically active ingredient of the composition for preventing or treating gastric cancer may be the ursodeoxycholic acid (UDCA) compound, and the urusdeoxycholic acid compound is a salt, preferably pharmaceutical It can also be used in the form of acceptable salts.
  • UDCA ursodeoxycholic acid
  • the salt is preferably an acid addition salt formed by a pharmaceutically acceptable free acid, and an organic acid and an inorganic acid may be used as the free acid.
  • the organic acid is not limited thereto, citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, Glutamic acid and aspartic acid.
  • the inorganic acid may include, but is not limited to, hydrochloric acid, bromic acid, sulfuric acid, and phosphoric acid.
  • Urusodeoxycholic acid is a component present in the bile of the animal in general, it can be used that is isolated from the bile of the animal or prepared by chemical synthesis known in the art, commercially available urusode Any of oxycholic acid can be used.
  • the separation can be obtained from the bile using the method of extracting and separating conventional materials.
  • the extraction can be extracted using a suitable solvent known in the art, that is, water or an organic solvent, preferably purified water, methanol (methanol), ethanol (ethanol), propanol, isopropanol ), Butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane
  • a suitable solvent known in the art, that is, water or an organic solvent, preferably purified water, methanol (methanol), ethanol (ethanol), propanol, isopropanol ), Butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane
  • a suitable solvent known in the art, that is, water or an organic solvent, preferably purified water,
  • separation and purification of urusodeoxycholic acid extracted using the extraction solvent is performed by column chromatography and high-speed liquid filled with various synthetic resins such as silica gel or activated alumina.
  • Chromatography HPLC; High Performance Liquid Chromatography
  • the method of extracting and separating and purifying the active ingredient is not necessarily limited to the above-mentioned methods, and any method used in the art may be used. It is possible.
  • the present invention is characterized by the first time that the urusodeoxycholic acid (UDCA) or salts thereof have the activity to prevent or treat gastric cancer.
  • UDCA urusodeoxycholic acid
  • urosodeoxycholine acid or a salt thereof of the present invention is characterized by having anticancer activity by inducing apoptosis in gastric cancer cells.
  • apoptosis control therapy is recently used to block the pathological growth of unregulated cells such as cancer cells.
  • Existing extensive necrosis drug therapy for diseases such as cancer Cytotoxic enzymes (e.g., lysozyme) leaked by killing pathological cells and destroying cell membranes of pathological cells show cytotoxicity to surrounding normal cells, which inevitably leads to excessive inflammation, resulting in high side effects. There is this.
  • cell apoptosis control therapy by apoptosis induces spontaneous killing of pathological cells or strongly inhibits the growth of these cells, which can reduce the inflammatory side effects induced by cell death of cancer cells compared to cell necrosis. There is this.
  • Apoptosis is genetically controlled programmed cell death, which refers to active cell death, and the apoptosis process requires energy and exhibits characteristic cell morphology.
  • the cell death is determined within the cell, and the cell death process is performed.
  • the cell shows characteristic biochemical and morphological changes, and when the cell death progresses, the cell contracts.
  • the cell membrane becomes bubble-like (blebbing), and the nucleus is condensed, the DNA in the nucleus is cut into small oligonucleotide fragments, forming an apoptotic body.
  • the apoptotic body thus formed undergoes a series of processes in which phagocytosis by macrophages causes cell death.
  • Apoptosis can also be broadly divided into two pathways, one is the mitochondrial regulatory endogenous pathway and the other is the exogenous pathway.
  • Exogenous pathways involve the assembly of a death inducing signaling complex (DISC) from activation of a death receptor (eg, FADD) induced by a ligand and thus the activation of the protease caspases.
  • DISC death inducing signaling complex
  • FADD death receptor
  • caspase 8 and 10 activates cleavage of caspase-3 and proceeds downstream of the caspase chain reaction pathway (U. Sartorius et al., Chembiochem 2 (2001) 20-29).
  • caspase-8 activates Bid and translocates it to the mitochondria, which releases cytochrome c into the cytoplasm.
  • Cytochrome c interacts with Apaf-1 and Apaf-1 activates caspase-9, which in turn activates caspase dependent pathways (EA Slee et al, J. Cell Biol. 144 (1999) 281-292) .
  • Mitochondria play a key role as modulators in the endogenous apoptosis pathway, where cellular damage is mediated by DNA damage, hypoxia, cellular stress or chemotherapeutic agents (A. Ashkenazi, Nature Reviews Cancer 2 (2002), 420-430). Disruption of the mitochondria leads to the release of SMAC / DIABLO and cytochrome c into the cytoplasm.
  • UDCA urosodeoxycholine acid
  • UDCA urosodeoxycholine acid
  • the initiation of the cell death mechanism is activated from the reaction of the death receptor and the ligand, and then the adapter associated with the cell death to the death receptor.
  • Factors are recruited and involved in oligomerization (Krammer PH. CD95 (APO-1 / Fas) -mediated apoptosis: Live and let die. Adv Immunol . 71: 163-210,1999).
  • TRAIL TNF-associated apoptosis-inducing ligand
  • TRAIL TNF-related apoptosis-inducing ligand
  • DR5 TNF-related apoptosis-inducing ligand
  • TNF Tumor Necrosis Factor
  • PKC protein kinase C
  • PKC protein kinase C
  • PKC also increases the transcription of certain genes.
  • the activity of PKC by DAG in secondary messengers produced by hydrolysis of phosphatidylinositol may be similarly expressed by the binding of monoacylglycerol or phorbol esters.
  • Phorbol esters have the function of a cancer promoter in animal cells and are known to induce the growth of cancer cells.
  • PKC is known to play an important role in the production of free radicals (ROS) in the cell
  • ROS free radicals
  • the production of free radicals such as superoxide anion in the cell is a flavoprotein-containing enzyme NADPH oxidase, It is known to occur through xanthine oxidase, NO synthase, and mitochondrial electron transport system.
  • PKCs are subdivided into three different subfamily and there are more than 12 isomeric forms in mammalian cells.
  • the activity of PKC ⁇ and migration into the cell membrane act to induce the initiation of apoptosis in cells, which is responsible for promoting the activity of caspase 3 and lower signal transduction to induction of apoptosis.
  • Known Brodie C and Blumberg PM.Regulation of cell apoptosis by protein kinase c ⁇ . Apoptosis . 8: 19-27,2003).
  • the present inventors analyzed whether caspases, which are cell death factors, are involved in apoptosis induction by UDCA.
  • UDCA a caspase inhibitor in a gastric cancer cell line
  • Treatment with UDCA and confirming the induction of apoptosis of cells showed that treatment with caspase inhibitors inhibited apoptosis by UDCA compared to the absence of treatment (see FIG. 2A). It has been shown that there is activity to increase (see FIG. 2B), and when the inhibitor of caspase 8 was treated, it was found that cleavage of caspase 3, 6 and PARP by activation of apoptosis did not occur (FIG. 2C). Reference).
  • the UDCA of the present invention can induce apoptosis by activating caspases in gastric cancer cells, which may be, but are not limited to, caspases-3, 6, 8 and 9, preferably Apoptosis can be induced by activating caspase-8 and cascaded caspases 3, 6 and 9 present downstream thereof.
  • the UDCA of the present invention is characterized by having an action of promoting the expression or activity of apoptosis receptors in gastric cancer cells, the apoptosis receptor is not limited thereto, DR3, DR4, DR5, DR6, FAS and TNFR It may include.
  • the expression of DR5 was increased when UDCA was treated to gastric cancer cells, whereas siRNA was used to suppress the expression of DR4, DR5 and FAS in gastric cancer cells. Subsequently, treatment with UDCA showed that apoptosis by UDCA was suppressed (see FIGS. 3A-3C).
  • UDCA when apoptosis is induced by UDCA in gastric cancer cells, to investigate the effect of UDCA on the expression or activity of cell death factors, ie FADD and RIP1, using siRNA After suppressing the expression of the gene, treatment of gastric cancer cells with UDCA showed that apoptosis was reduced compared to the control (see FIGS. 4A and 4B).
  • the UDCA of the present invention promotes expression or activity of apoptosis receptors in gastric cancer cells, and activation of such apoptosis receptors promotes apoptosis by promoting the activity of adapter factors (eg, FADD or RIP1) associated with cell death.
  • adapter factors eg, FADD or RIP1
  • the present inventors examined whether UDCA can activate PKC in a cell death mechanism of gastric cancer cells by UDCA, and according to an embodiment of the present invention, after treating UDCA to gastric cancer cell lines, cytoplasmic fraction and membrane of cells The fractions were extracted and Western blots were used to confirm the positional shifts of the PKC isomers in the cells. In the case of PKC ⁇ , the migration from the cytosol to the membrane by UDCA was confirmed (see FIG. 5A).
  • the present inventors found that the activity of the death receptor DR5 and caspases in the apoptosis of cancer cells by UDCA is regulated by PKC ⁇ , so that PKC ⁇ plays a very important role in the initiation of apoptosis of cancer cells by UDCA. I could see that.
  • ROS reactive oxygen species
  • ROS reactive oxygen species
  • radical a singlet oxygen, hydrogen, as well as radicals such as superoxide anion radicals (O2-), hydroxyl radicals (OH.), Peroxyl radicals (ROO), and the like. It refers to all non-radical materials such as peroxide, etc. Its variety is very diverse, and the reaction time of ROS is very short while the reaction force is very large, so that it is possible to denature various proteins, lipid peroxidation and DNA in vivo.
  • ROS is involved in the anticancer activity of gastric cancer of UDCA.
  • UDCA when UDCA was treated to gastric cancer cells, the production of ROS increased and cell death was increased.
  • treatment with ROS scavenger reduced ROS production and decreased cell death (see FIGS. 6A to 6C).
  • FIGS. 7A, 7B, 8A, and 8B Expression of DR5 by UDCA and PKC ⁇ activity (from cytosol to membrane) It can be seen that the movement of is also regulated by ROS production (see FIGS. 7A, 7B, 8A, and 8B), and the fact that UDCA has an effect of inducing ROS production was first identified in the present invention.
  • cholesterol present in the cell membrane of eukaryotic cells is a component that plays a very important role in the composition, maintenance and fluidity of the membrane, such cholesterol is not formed in a uniform form in the cell membrane but is formed in a dense form at a specific site, This site in the stomach is referred to as "lipid raft".
  • these lipid raft domains contain relatively high amounts of cholesterol and glycosphingolipids, and include signal transduction proteins such as Src-family kinase, hetero-trimeric G protein subunits, and receptor tyrosine kinase to activate the phosphorylation chain reaction.
  • signal transduction proteins such as Src-family kinase, hetero-trimeric G protein subunits, and receptor tyrosine kinase to activate the phosphorylation chain reaction.
  • MBCD a reagent that removes cholesterol from lipid rafts and damages the structure of lipid rafts, in order to investigate whether lipid raft domains are involved in the death signal transmission process of cancer cells by UDCA, in particular, apoptosis.
  • UDCA death signal transmission process of cancer cells by UDCA
  • apoptosis by UDCA was observed, and MBCD treatment resulted in inhibition of caspases activity by UDCA, decreased expression of DR5 and ultimately suppressed apoptosis (FIG. 9, 10A and 10B).
  • the present inventors have found that the structure of the lipid raft domain present in the cell membrane during the apoptosis process of gastric cancer cells by the UDCA of the present invention acts as an important regulator of cell death signal transduction.
  • ursodeoxycholic acid (UDCA) of the present invention is effective in treating gastric cancer by inducing cell death in gastric cancer cells, and the gastric cancer cells in the present invention may include any gastric cancer cells. And for example snu-601, snu-638, snu-1 and snu-216.
  • the present invention can provide a composition for preventing or treating gastric cancer, which includes ursodeoxycholic acid (UDCA) or a salt thereof as an active ingredient.
  • UDCA ursodeoxycholic acid
  • the composition for preventing or treating gastric cancer may include a pharmaceutically effective amount of the urousodeoxycholic acid compound alone or may include one or more pharmaceutically acceptable carriers, excipients or diluents.
  • the pharmaceutically effective amount in the above means an amount sufficient to prevent, ameliorate and treat gastric cancer symptoms.
  • the pharmaceutically effective amount of urosodeoxycholic acid according to the present invention is 0.1 to 1,500 mg / day / kg body weight, preferably 0.5 to 900 mg / day / kg body weight.
  • the pharmaceutically effective amount may be appropriately changed depending on the degree of gastric cancer symptoms, the age, weight, health condition, sex, route of administration and duration of treatment of the patient.
  • pharmaceutically acceptable refers to a composition that is physiologically acceptable and does not normally cause an allergic reaction, such as gastrointestinal disorders, dizziness, or the like when administered to a human.
  • Examples of such carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives may be further included.
  • compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
  • the formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.
  • composition for preventing or treating gastric cancer symptoms according to the present invention may be administered through various routes including oral, transdermal, subcutaneous, intravenous or muscle, and the dosage of the active ingredient is determined by the route of administration, age, sex, weight and It may be appropriately selected depending on various factors such as the severity of the patient.
  • the composition for preventing or treating gastric cancer of the present invention can be administered in parallel with a known compound having the effect of preventing, improving or treating gastric cancer symptoms.
  • the present invention may provide a method for preventing or treating gastric cancer, comprising administering urosodeoxycholic acid to a subject in need thereof except a human with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier May be used at least one selected from the group consisting of diluents, lubricants, binders, disintegrants, sweeteners, stabilizers and preservatives.
  • the present invention can provide an apoptosis inducer composition comprising ursodeoxycholic acid (UDCA) or a salt thereof as an active ingredient, and the apoptosis inducer composition according to the present invention can induce apoptosis in gastric cancer cells.
  • UDCA ursodeoxycholic acid
  • the apoptosis inducer composition according to the present invention can induce apoptosis in gastric cancer cells.
  • cancer is caused mostly by an imbalance between cell death by apoptosis and cell proliferation by intracellular signal transduction mechanisms.
  • the signal transduction mechanisms involved in cell proliferation are activated, whereas cells related to apoptosis are activated. It is well known in the art that internal signal transduction is inhibited.
  • apoptosis inducers are effective in treating cancer by activating apoptosis in cancer cells and inducing planned cell death in cancer cells.
  • the apoptosis can be induced through any apoptosis activity mechanism occurring in the cell, and preferably, by the treatment of urosodeoxycholine acid (UDCA), caspase in gastric cancer cells (caspase) Promotion of activity); Promoting activity or expression of apoptosis receptors; Translocation of the protein kinase C (PKC) ⁇ protein from the cytosol to the membrane; Or by the generation of reactive oxygen species (ROS).
  • UDCA urosodeoxycholine acid
  • caspase caspase in gastric cancer cells
  • ROS reactive oxygen species
  • gastric cancer prevention or treatment composition and apoptosis inducer composition comprising the urusodeoxycholic acid (UDCA) or a salt thereof according to the present invention as an active ingredient in an amount of 250 ⁇ M to 1000 ⁇ M based on the total weight of the composition. May be included.
  • UDCA urusodeoxycholic acid
  • Ursodeoxycholic acid was purchased from ICN Biomedical or Sigma, and Deoxycholic acid (DCA), Z-DEVD-FMK (caspase-3 inhibitor) ), Z-VEID-FMK (caspase-6 inhibitor), Z-IETD-FMK (caspase-8 inhibitor), Z-LEHD-FMK (caspase-9 inhibitor), Z-VAD-FMK (poly-caspase inhibitor) Ac-LEVD-CHO (caspase-4 inhibitor) was purchased from Calbiochem and used N-acetyl-L-cysteine (NAC), Butylated hydroxyanisole (BHA) and 1,2-dihydroxybenzene-3, 5-disulforic acid (Tiron) was purchased from Roche, Methyl- ⁇ -Cyclodextrin (MBCD), catalase and DPI were purchased from Sigma Aldrich, UO126, PD98059, Rottlerin,
  • Cleaved caspase-3 (Asp175) antibody, Cleaved caspase-6 (Asp315) antibody, p-MEK1 / 2 antibody, t-MEK1 / 2 antibody, p-EGFR antibody and t-EGFR antibody were P-ERK1 / 2 antibody, t-ERK1 / 2 antibody, FADD antibody, Caveolin-1, Goat anti-mouse IgG-HRP antibody and Goat anti-rabbit IgG-HRP were used from Cell signaling.
  • Antibodies were purchased from Santa Cruz Biotechnology Inc., and anti-PARP antibodies, RIP1 antibodies, PKC ⁇ , PKC ⁇ , PKC ⁇ and PKC ⁇ were those purchased from BD pharmingen.
  • DR4 antibody and DR5 antibody were used from ProSic, and Tubulin was used from Biogenex Laboratories.
  • the cells used in the following examples used human gastric cancer cell lines (snu-601, snu-638, snu-1 and snu-216 cells), and the cells were obtained from the Korea Cell Line Bank of Seoul National University (Korea) These cells were RPMI 1640 medium (Invitrogen, CA) supplemented with heat-inactivated 10% fetal bovine serum (FBS; Invitrogen, CA) and 1% penicillin-streptomycin (Welzen, Seoul, Korea). Incubated at 37 ° C. and at 5% carbon dioxide conditions.
  • FBS fetal bovine serum
  • penicillin-streptomycin Welzen, Seoul, Korea
  • the cells were also incubated overnight for drug exposure testing, then 5 ⁇ 10 6 cells / 20 cm 2 dish, 1.5 ⁇ 10 6 cells / 10 cm 2 dish, 5 ⁇ 10 5 cells / 6 cm 2 dish, 2 ⁇ 10
  • the cells were divided into 5 cells / 3.5 cm 2 dishes, and in the case of 24 well plates, cells were divided and used to have a cell number of 5 ⁇ 10 4 cells / well.
  • UDCA urosodeoxycholine acid
  • the MTT assay is treated with 0.5 ⁇ g / ml MTT to each of the cells cultured after treatment with UDCA and incubated for 4 hours, the cells of each plate collected and collected at room temperature for 5 minutes at 1000 rpm for 5 minutes Centrifuged. The medium was then removed, 750 ul of DMSO was added to dissolve the formazin crystal, and the absorbance was measured at 540 nm using an ELISA microplate reader (Pekin-Elmer). In this case, cells treated with nothing were used as a control group, and the cell viability of the cells was measured based on 100%.
  • HO Hoechst 33342
  • PI Propidium Iodide
  • HO / PI double staining using this principle is performed by dispensing snu-601, snu-638, snu-1 and snu-216 cells into 2 ⁇ 10 5 cells / 3.5 cm 2 dishes, respectively, followed by the same concentration as in the MTT assay.
  • UDCA and cells were stained by treating the cells with 1 ⁇ g / ml Hoechst 33342 and 5 ⁇ g / ml PI for each hour. Cells were then collected by treatment with trypsin, centrifuged at 1500 rpm for 10 minutes at a temperature of 4 ° C., and the cells collected at the bottom were washed with 1 ⁇ cold PBS solution and then centrifuged again as above conditions.
  • LDH lactate dehydrogenase
  • snu-601, snu-638, snu-1 and snu-216 cells are each dispensed into 5 ⁇ 10 4 cells / well in a 24-well plate, incubated in 500 ul RPMI medium, and the method described above.
  • UDCA was treated for each concentration in the same manner.
  • 50ul of LDH lysis buffer was added 30 minutes before the end of constant culture time of each cell to lyse the cells. Lysed cells were centrifuged at 600 g for 10 minutes, each supernatant was placed in a 24-well micro-dispensing plate of 10 ul, followed by 100 ul of LDH reaction mixture (mix of 200 ul of WST substrate mixture and 10.5 ml of LDH assay buffer).
  • the plate was stirred at room temperature for 30 minutes, and measured at a wavelength of 450 nm and a reference wavelength of 650 nm at a primary wavelength using a plate reader (Bio Rad, USA).
  • the percent release of LDH released from each cell was calculated by the following formula.
  • Toxicity [(Experimental LDH Release)-(Spontaneous LDH Release by Effector or Target) / (LDH Release Maximum)-(Voluntary LDH Release)] ⁇ 100%
  • LDH activity spontaneously released from control cells was less than 2% LDH release maximum measured from fully lysed cells.
  • the UDCA was treated for 12 hours at concentrations of 250, 500, and 1000 ⁇ M for the gastric cancer cell lines, respectively, followed by 37 ° C./5% CO. 2 Under conditions Incubate for 2 weeks and the colonies were stained with crystal violet to analyze the degree of colony formation through the colony formation assay. At this time, the measurement of the degree of colony formation was visually observed colonies formed on the plate (> 1mm).
  • gastric cancer cell lines were treated with UDCA and subjected to double staining using HO / PI, gastric cancer cells were confirmed to induce cell death by apoptosis, whereas cell necrosis in all gastric cancer cell lines was associated with apoptosis. Almost no induction was observed.
  • lactate dehydrogenase (LDH) release analysis showed that the activity of LDH was almost 1% or less in gastric cancer cell lines treated with UDCA.
  • LDH lactate dehydrogenase
  • cell death of gastric cancer cells by UDCA of the present invention is caused by apoptosis rather than cell necrosis.
  • UDCA induces cell death by apoptosis in gastric cancer cells, but does not induce cell death by cell necrosis.
  • DCA Deoxycholine acid
  • DCA treatment similarly to the treatment of gastric cancer cells with UDCA, DCA treatment also induced apoptosis of gastric cancer cells in a concentration-dependent manner, but HO / PI double staining showed 0.5 mM DCA.
  • Abnormal treatment resulted in a significant decrease in apoptotic body percentage compared to UDCA treatment.
  • DCA was shown to induce cell necrosis in gastric cancer cells, unlike UDCA.
  • gastric cancer cells were found to increase the release of LDH out of the cell membrane in a concentration-dependent manner.
  • DCA has an activity of inducing apoptosis of gastric cancer cells, but unlike UDCA, the mechanism of inducing cell death is achieved through cell necrosis, which is treated with UDCA in FIG. 1A.
  • Apoptotic bis are formed without LDH release, which is supported by the presence of LDH release when treated with DCA.
  • the present inventors performed the following experiment to confirm the effect of caspases on the apoptosis action by UDCA as UDCA confirms that the UDCA induces apoptosis in gastric cancer cells, resulting in cell death.
  • 5 ⁇ 10 5 gastric cancer cells were treated with 1000 ⁇ M of UDCA, and then cultured for 12, 18, 24 and 48 hours, respectively, and the cells were collected by centrifugation.
  • the cells were then lysed with 50 ul of cold cell lysis buffer, incubated on ice for 10 minutes and centrifuged at 4 ° C. for 1 minute at 10,000 g. Transfer the supernatant to a new tube, quantify using the Biorend Protein Assay Kit, dilute to 150 ul to 50 ul with cell lysis buffer, 50 ul of 2x reaction buffer (containing 10 mM DTT) and 5 ul of 4 mM IETD- pNA substrate was added to a final concentration of 200 ⁇ . The cells were incubated at 37 ° C. for 2 hours, and the absorbance was measured at 405 nm using a plate reader. As a control, untreated cells were used.
  • the present inventors treated Z-IETD-FMK (20 ⁇ M), an inhibitor of caspase 8, with the gastric cancer cell line for 1 hour in advance in order to confirm the importance of caspase 8 in apoptosis of gastric cancer cells by UDCA, 1000 ⁇ M of UDCA was treated to snu-601 (for 24 hours) and snu-638 cells (for 36 hours), respectively, and the amount of protein of cleaved caspase 3, cleaved caspase 6, cleaved PARP and tubulin was measured. Confirmed by performing blots.
  • apoptosis induction of gastric cancer cells by UDCA was shown to be inhibited when treated with caspase inhibitors, more specifically caspase-3 inhibitors (Z-DEVD-FMK) , Caspase-6 inhibitor (Z-VEID-FMK), caspase-7 inhibitor (Z-IETD-FMK), caspase-8 inhibitor (Z-LEHD-FMK), or pan-caspase inhibitor Z-VAD-FMK
  • caspase inhibitors more specifically caspase-3 inhibitors (Z-DEVD-FMK)
  • Caspase-6 inhibitor Z-VEID-FMK
  • caspase-7 inhibitor Z-IETD-FMK
  • caspase-8 inhibitor Z-LEHD-FMK
  • pan-caspase inhibitor Z-VAD-FMK pan-caspase inhibitor
  • caspase 8 The activity of caspase 8 was shown to increase in activity by treatment of UDCA (see FIG. 2B).
  • FIG. 2C western blot after treatment with caspase-8 inhibitor to confirm whether caspase 8 plays an important role, as shown in FIG. 2C, caspase 3, 6 , And sections with PARP cleaved were not observed. This is more evident compared to the Western blot results on the right side of FIG. 2A.
  • UDCA increases caspase 8 activity in the process of inducing apoptosis of gastric cancer cells by UDCA, thus inducing apoptosis of cells by a signal transduction system related to caspase 8 downstream.
  • caspase 8 and caspase 3, 6, and 9 were related to apoptosis of gastric cancer cells by UDCA.
  • the maximum activity of caspase-8 is observed at 24 hours in snu-601 but is delayed at this time in snu-638.
  • the time point for examining the apoptosis mechanism in snu-601 cells is 24 hours. 36 hours were selected for snu-536.
  • cell surface killing receptors such as DR4, DR5 and FAS play an important role in the induction of cell death in cancer cells.
  • the present inventors investigated whether cell surface killing receptors such as DR4, DR5 and FAS are involved in apoptosis induction of gastric cancer cells by UDCA.
  • siRNAs of cell surface killing receptors described in Table 1 below that is, siRNA (8ug) of each receptor was transferred to 1 ⁇ 10 6 cells of gastric cancer cells. Cells transfected with siRNA were incubated for 40 hours at 37 ° C. and 5% carbon dioxide, and then treated with 1000 ⁇ M of UDCA, respectively, and cultured for a period of time (24 or 36 hours). Then, caspase-8 activity, MTT assay and HO / PI double staining assay were performed in the same manner as described in the above examples.
  • siRNA sequence Cell surface death receptor siRNA sequence SEQ ID NO: siRNA FAS (S) 5'-GCUUAUACAUAGCAAUGGU (dtdt) -3 ' One siRNA FAS (AS) 5'-ACCAUUGCUAUGUAUAAGC (dtdt) -3 ' 2 siRNA RIP1 (S) 5'-CACACAGUCUCAGAUUGAU (dtdt) -3 ' 3 siRNA RIP1 (AS) 5'-AUCAAUCUGAGACUGUGUG (dtdt) -3 ' 4 siRNA FADD (S) 5'-CCAAGAUCGACAGCAUCGA (dtdt) -3 ' 5 siRNA FADD (AS) 5'-UCGAUGCUGUCGAUCUUGG (dtdt) -3 ' 6 siRNA DR4 (S) 5'-CUGGAAAGUUCAUCUACUU (dtdt) -3 ' 7 siRNA DR4 (AS) 5'-AAGUAGAUGAACU
  • apoptosis of cells by UDCA was found to decrease apoptosis when siRNA DR5 or siRNA FAS was introduced in snu-601 cells, whereas apoptosis was reduced by siRNA DR4. Turned out not to be.
  • siRNA DR4 or siRNA DR5 in snu-638 cells has been shown to reduce apoptosis
  • siRNA FAS has not been shown to reduce apoptosis.
  • 6 and PARP activity was the same result (see Fig. 3B).
  • the results indicate that the apoptosis induction process of gastric cancer cells by UDCA is regulated by DR5 and FAS in snu-601 cells and by DR4 or DR5 in snu-638 cells.
  • DR5 induces a regulatory action, ie the onset of apoptosis by UDCA, in both gastric cancer cells.
  • TRAIL When apoptosis is induced in cells, TRAIL generally binds to the death receptors DR4 and DR5, and FAS ligands are characterized by inducing FADD to bind to FAS through their killing effect domains. Caspase 8 is induced to bind, resulting in the assembly of apoptosis inducing signal complexes to the receptor.
  • the present inventors transduced siRNA FADD and siRNA RIP1 described in Example 3 into gastric cancer cells, and then treated and cultured with 1000 ⁇ M of UDCA. Then, the HO / PI double staining method, the Western blot and the caspase 8 activity measuring method described in the above examples were performed, respectively.
  • the apoptosis level of the cells by UDCA was reduced by siRNA FADD and siRNA RIP1 in both the cells of snu-601 and snu-638.
  • the activity of caspase 3, 6 and PARP was also reduced by siRNA FADD and siRNA RIP1.
  • the activity of caspase 8 was also shown to be reduced by siRNA FADD and siRNA RIP1.
  • PKC ⁇ is a type of PKC super family that is known to be involved in cell apoptosis, and when PKC ⁇ is transported to the cell membrane, mitochondria and nucleus, it activates specific mechanisms to activate caspase 3 and ultimately induce apoptosis, thus, The activity of PKC is reported to be due to redistribution of kinase at cytosol and other intracellular locations.
  • the present inventors treated 1000 ⁇ M of UDCA in gastric cancer cells, and then cultured each hour (0, 1, 2, 4, 8 and 12 hours).
  • Cellular proteins (fraction 1) and organ / membrane proteins (fraction 2) were extracted using the Proteoextract subcellular proteome extraction kit (Calbiochem), and PKC ⁇ , PKC ⁇ , PKC ⁇ , and PKC ⁇ cytosolic membranes were extracted by Western blot. The shift was analyzed.
  • the treatment of UDCA had the effect of shifting PKC ⁇ from the cytosol to the membrane, and the migration of PKC ⁇ to the cell membrane was performed prior to the apoptosis of cells by UDCA (snu-601, UDCA). 2-4 hours after treatment, and 4-8 hours after UDCA treatment in snu-638). In PKC ⁇ , PKC ⁇ and PKC ⁇ , no significant shift to the cell membrane was observed.
  • the present inventors treated 5 ⁇ M rottlerin, ie, PKC ⁇ inhibitors, and 1000 ⁇ M UDCA for gastric cancer cell lines, respectively, in order to confirm the degree of change in apoptosis by UDCA by treating the inhibitor of PKC ⁇ . Then, Western blot was performed using double staining of HO / PI and antibodies of caspases. Furthermore, after transduction into gastric cancer cells using siRNA PKC ⁇ , the expression level of caspases in the cells was confirmed by Western blot. It was. In addition, in addition to the above-described inhibitor of PKC ⁇ , roletrin, other PKC inhibitors, GF109203X (1 ⁇ M), and PKC ⁇ inhibitor GO6979 (1 ⁇ M) were also tested.
  • the present inventors have found that when UDCA is treated in gastric cancer cells, PKC ⁇ is induced by UDCA to the cell membrane and induces apoptosis through activation of cell death factors.
  • UDCA induces the expression of DR5 in gastric cancer cells through the above-described examples, to analyze the relationship between DR5 and PKC ⁇ in apoptosis by UDCA, 5 ⁇ M of rottlerin in gastric cancer cell lines.
  • Western blot was performed to investigate the expression level of DR5, and also after transducing siRNA PKC ⁇ into gastric cancer cell lines, treated with UDCA and Western blot Was performed to investigate the expression level of DR5 and PKC ⁇ .
  • ROS Reactive oxygen species
  • the present inventors treated 1000 ⁇ M of UDCA in gastric cancer cell lines to confirm whether ROS are involved in apoptosis of gastric cancer cells by UDCA, and then analyzed the degree of ROS generation after 3 hours or 5 hours of incubation. Double staining of PI was performed, and the expression level of caspases was confirmed by Western blot.
  • scavengers of ROS, NAC (10 mM), BHA (100 ⁇ M), Trion (10 mM), DPI (2 ⁇ M), and catalase (1000U), respectively were added to the gastric cancer cells through the same method as described above. The degree of apoptosis was measured.
  • the ROS assay was divided into 5 ⁇ 10 4 cell number of gastric cancer cells in a 24-well plate, incubated with 500ul RPMI medium, and then treated with UDCA and the cells were again cultured under the same conditions. Then, 50 ⁇ M of 2 ', 7'-dichlorofluorescein diacetate (DCFDA, Molecular probe) and 0.5 ⁇ g / ml of HO were added to each cell to confirm the generation of reactive oxygen species (ROS) and incubated for 1 hour. It was.
  • DCFDA reactive oxygen species
  • DCFDA was measured using a fluorocount model MQM200 plate reader (Packard instrument, USA) at an excitation wavelength of 490 nm and an emission wavelength of 530 nm, and the measurement of HO was performed at an excitation wavelength of 340 nm and of 425 nm. Measured at the emission wavelength. The amount of ROS produced was calculated by measuring the ratio of DCFDA / HO per well.
  • the inventors added NAC or BHA, which is a scavenger of UDCA and ROS, to the gastric cancer cells, respectively, and examined DR5 through Western blot to investigate how the expression of ROS is induced by UDCA. The expression level of was investigated.
  • DR5 induced by UDCA in gastric cancer cells was found to have decreased expression by NAC and BHA.
  • the results indicate that the expression of DR5 by UDCA is regulated by the production of ROS, and furthermore, ROS acts as another important regulator in the expression of DR5 by UDCA.
  • PKC ⁇ is known as a factor present downstream of the ROS generation mechanism. Therefore, the present inventors performed an experiment to determine whether the production of ROS regulates the trasnlocation of PKC ⁇ during apoptosis of gastric cancer cells by UDCA, that is, 1 hour treatment of 10 mM of NAC for gastric cancer cell lines for 1 hour.
  • the results indicate that the migration of PKC ⁇ by UDCA is regulated by the production of ROS, and PKC ⁇ is present downstream of the ROS production mechanism in the process of apoptosis by UDCA in gastric cancer cells. It was confirmed that the factor.
  • Cholesterol has been known to play a very important role in the composition, maintenance and fluidity of the membrane.
  • a cholesterol-rich microdomain also known as a lipid raft, plays an important role in signal transduction of apoptosis and is associated with plasma cholesterol associated with the formation of FAS-FADD, DR4 or DR5-FADD complexes and activation of caspase 8 It is known to play an important role in the change.
  • the present inventors used MBCD, a lipid raft deficient reagent, to investigate the relationship between apoptosis and lipid raft of gastric cancer cells by UDCA.
  • the gastric cancer cell line was treated with a vehicle or UDCA for 8 hours.
  • the gastric cancer cell line treated with 0.5 or 1 mM MBCD for 1 hour, and then treated with 1000 ⁇ M of UDCA, followed by incubation for 24 and 36 hours, respectively, MTT assay, HO / PI double staining method and caspase 8 activity
  • MTT assay MTT assay
  • HO / PI double staining method MTT assay
  • caspase 8 activity MTT assay
  • Example 7 confirmed that the lipid raft plays a very important role in the cell death mechanism of gastric cancer cells by UDCA, whether the lipid raft is also involved in the activity of the ROS / PKC ⁇ confirmed through the previous embodiment Investigated.
  • FIGS. 11A-11B the cytosolic migration of PKC ⁇ by UDCA to membranes in gastric cancer cells was shown to be inhibited due to the treatment of MBCD (see FIG. 11A), and through these results PKC ⁇ It can be seen that is a downstream event of lipid raft during apoptosis of cells.
  • ROS production assays showed that ROS production by UDCA in gastric cancer cells was reduced due to the treatment of MBCD (see FIG. 11B).
  • lipid raft is a function of DR5 by UDCA production of ROS and movement of PKC ⁇ from cytosol to cell membrane. It was found that it acts as a very important regulator of apoptosis in gastric cancer cells.
  • mice 6-week-old Athymic balb / c nude mice were purchased (Orien Bios, Korea) and snu-601 cells in the flank region of these mice. was injected ssikeul 5 ⁇ 10 6 gae / 200ul (subcutaneous injection). From the day after injecting gastric cancer cells (day 1), 10 mice per group were administered intraperitoneally with UDCA solution (150mg / kg / day, 6days / week) or carrier (volume) formed from day 14 was measured and the experiment was continued until day 33. Tumor size was expressed as relative value of mean tumor size formed on day 14. The body weight of the mice was also measured during the experiment, and no significant difference in body weight was observed between the UDCA treated group and the control group. Statistical significance was confirmed by paired T-test.
  • Figs. 12A and 12B compared with the control group administered the carrier 300ul after snu-601 cell injection (upper line in Fig. 12A and the line in Fig. 12B), 300ul of UDCA after snu-601 cell injection. It can be seen that the tumor size of mice (bottom of FIG. 12A and line ⁇ of FIG. 12B) of the group to which 300 ul of the solution was administered decreased noticeably.
  • the present invention is a result supported by the following Korean national R & D projects:

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur une composition destinée à la prévention ou au traitement du cancer de l'estomac, contenant de l'acide ursodésoxycholique (UDCA) ou un sel de ce dernier en tant que principe actif, et plus précisément la présente invention porte sur une composition destinée à la prévention ou au traitement du cancer de l'estomac, comprenant de l'acide ursodésoxycholique ou un sel de ce dernier en tant que principe actif, et concerne un procédé destiné à la prévention ou au traitement du cancer de l'estomac, comprenant l'étape d'administration d'une composition d'un agent inducteur d'apoptose et d'acide ursodésoxycholique ou d'un sel de ce dernier, en même temps qu'un support pharmaceutiquement acceptable, à un individu qui en a besoin. L'acide ursodésoxycholique ou le sel de ce dernier selon la présente invention peut être avantageusement utilisé pour la prévention ou le traitement du cancer de l'estomac, car il a une remarquable activité d'activation de la caspase, et finalement pour induire une apoptose dans des cellules du cancer de l'estomac, par induction de l'activité de PKC et promotion de la croissance d'espèces réactives de l'oxygène (ROS) d'une manière qui dépend des radeaux lipidiques dans les cellules du cancer de l'estomac, et ajustement de l'expression ou de l'activité des récepteurs de la mort cellulaire (superfamille du récepteur du TNF).
PCT/KR2010/005080 2010-01-28 2010-08-02 Composition pour la prévention ou le traitement du cancer de l'estomac, contenant de l'acide ursodésoxycholique en tant que principe actif Ceased WO2011093559A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0007709 2010-01-28
KR1020100007709A KR101131675B1 (ko) 2010-01-28 2010-01-28 우루소데옥시콜린산을 유효성분으로 함유하는 위암의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2011093559A1 true WO2011093559A1 (fr) 2011-08-04

Family

ID=44319521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005080 Ceased WO2011093559A1 (fr) 2010-01-28 2010-08-02 Composition pour la prévention ou le traitement du cancer de l'estomac, contenant de l'acide ursodésoxycholique en tant que principe actif

Country Status (2)

Country Link
KR (1) KR101131675B1 (fr)
WO (1) WO2011093559A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021119096A1 (fr) * 2019-12-09 2021-06-17 Tyme, Inc. Compositions et procédés pharmaceutiques
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
US11607418B2 (en) 2020-05-14 2023-03-21 Tyme, Inc. Methods of treating SARS-CoV-2 infections

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160022433A (ko) 2014-08-19 2016-03-02 아주대학교산학협력단 디클로로아세테이트를 유효성분으로 함유하는 위암에 대한 항암활성 보조제
CN114867482B (zh) * 2019-12-13 2024-12-31 诚信生物有限公司 用于预防或治疗癌症的药物组合物
JP7376718B2 (ja) * 2019-12-13 2023-11-08 株式会社ベリタスバイオセラピューティクス 癌の予防または治療用薬学組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155977B1 (ko) * 1995-03-23 1998-11-16 서치영 항암조성물
KR20080061327A (ko) * 2006-12-27 2008-07-02 성균관대학교산학협력단 가용성 ｕｄｃａ를 포함하는 직장암 예방 및 치료 조성물
EP2208497A1 (fr) * 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Utilisation d'acide ursodeoxycholique (UDCA) pour améliorer la condition de santé générale d'un patient ayant une tumeur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155977B1 (ko) * 1995-03-23 1998-11-16 서치영 항암조성물
KR20080061327A (ko) * 2006-12-27 2008-07-02 성균관대학교산학협력단 가용성 ｕｄｃａ를 포함하는 직장암 예방 및 치료 조성물
EP2208497A1 (fr) * 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Utilisation d'acide ursodeoxycholique (UDCA) pour améliorer la condition de santé générale d'un patient ayant une tumeur

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
WO2021119096A1 (fr) * 2019-12-09 2021-06-17 Tyme, Inc. Compositions et procédés pharmaceutiques
US11607418B2 (en) 2020-05-14 2023-03-21 Tyme, Inc. Methods of treating SARS-CoV-2 infections

Also Published As

Publication number Publication date
KR101131675B1 (ko) 2012-03-28
KR20110088007A (ko) 2011-08-03

Similar Documents

Publication Publication Date Title
Ni et al. Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke
Lv et al. Corilagin alleviates acetaminophen-induced hepatotoxicity via enhancing the AMPK/GSK3β-Nrf2 signaling pathway
Fu et al. Genistein induces pancreatic β-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice
Kim et al. Synergistic activation of JNK/SAPK induced by TNF-α and IFN-γ: apoptosis of pancreatic β-cells via the p53 and ROS pathway
WO2011093559A1 (fr) Composition pour la prévention ou le traitement du cancer de l'estomac, contenant de l'acide ursodésoxycholique en tant que principe actif
Esfandyari et al. The protective effect of sulforaphane against oxidative stress through activation of NRF2/ARE pathway in human granulosa cells
US6953786B2 (en) Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
WO2017078440A1 (fr) Peptide présentant des effets de prévention et de régénérescence de la perte neuronale, et composition le contenant
WO2017007162A1 (fr) Composition d'acide azélaîque ayant un effet de dégradation des triglycérides du tissu adipeux
WO2010053314A2 (fr) Composition pour la prévention ou le traitement du cancer contenant comme principe actif une lignée cellulaire de cellules souches végétales extraite du panax ginseng incluant le ginseng sauvage ou le ginseng
WO2020116810A1 (fr) Composition pharmaceutique, comprenant un peptide inhibiteur contre la signalisation fas, destinée à la prévention ou au traitement de l'obésité, du foie gras, ou de la stéatohépatite
Wang et al. Ghrelin inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line
WO2015111832A1 (fr) Composition de prévention ou de traitement de maladies liées à la prostate, contenant un extrait de poncirus trifoliata
Chen et al. Nicorandil prevents doxorubicin-induced human umbilical vein endothelial cell apoptosis
Uberti et al. Contribution of NF-κB and p53 in the glutamate-induced apoptosis
WO2017078405A9 (fr) Composition pharmaceutique pour le traitement du cancer du poumon comprenant un composé à base de glucocorticoïde
WO2020091463A1 (fr) Composition pharmaceutique comportant des mitochondries isolées pour prévenir ou traiter la ténopathie
WO2018080146A2 (fr) Composition comprenant un peptide inhibiteur de protéine phosphatase 1 pour le traitement des maladies vasculaires
WO2010011111A4 (fr) Composition contre le vieillissement et/ou pour l'allongement de la durée de vie, contenant du dapsone en tant que principe actif
WO2020122391A1 (fr) Composition pour la prévention ou le traitement de maladies associées à la sénescence cellulaire, contenant de l'homoharringtonine en tant que principe actif
WO2017023047A1 (fr) Composition pour la prévention ou le traitement d'une maladie inflammatoire ou du cancer contenant de l'aripiprazole en tant qu'ingrédient actif
WO2023182567A1 (fr) Peptide ayant une activité antidiabétique, complexe peptidique et son utilisation
WO2014051359A1 (fr) Composition pharmaceutique comprenant de la néférine comme ingrédient actif de prévention contre un hépatome ou de traitement de ce dernier
WO2015147369A1 (fr) Composition pharmaceutique contenant un inhibiteur de sirt2
WO2024215162A1 (fr) Protéine de fusion unique et composition pharmaceutique la comprenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10844783

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10844783

Country of ref document: EP

Kind code of ref document: A1